FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549
-------------	------	-------

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* Francois Cedric					2. Issuer Name and Ticker or Trading Symbol Apellis Pharmaceuticals, Inc. [APLS]										5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner						
,	,		3. Date of Earliest Transaction (Month/Day/Year) 04/25/2022										X Officer (give title Other (specify below) below) Chief Executive Officer								
AM M	Α	4.	4. If Amendment, Date of Original Filed (Month/Day/Year)										Form filed by Mars than One Reporting 6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by Mars than One Reporting								
(S	tate)	(Zip)											Person								
	Tab	le I	- Non-Deri	ivativ	re Sec	urit	ies A	cqu	ired,	Dispo	sed	of, or	Benef	iciall	y Owned						
1. Title of Security (Instr. 3)			Date	rear)	2A. Deemed Execution Date, if any (Month/Day/Year)		ite,	3. Transaction Code (Instr. 8)						5)	Securities Beneficially Owned Fol	y	Form: D (D) or Ir	orm: Direct D) or Indirect		ficial ership	
								Code	v	Amoun	t	(A) or (D)	Price		Transaction				(mou.	. 4)	
Stock		04/25/202		22				J	Ш	12,50	00(1)	D	\$()	943,440		D				
Stock			12/19/202	22				M ⁽²⁾		28,2	00	A	\$2 .	67	971,640) D				
mon Stock 12/19/20		12/19/202	22	,			M		15,0	00	Α	\$3.	76	986,640		0 D					
mon Stock 12/19/20		12/19/202	22				M		6,68	38	A	\$14	.95	993,328		28 D					
Common Stock 12/19/2		12/19/202	22	2			S ⁽²⁾		3,75	51	D	\$51.90	578(3)	989,577		7 D					
mmon Stock 12/19/202		22				S ⁽²⁾		24,4	49	D	\$52.00	597(4)	965,1	128		D					
Common Stock															300,0	300,000		I ⁽⁵⁾ Fra		ssi	
Common Stock															234,411		I(e)		The Francois- DuBois Educational Trust		
	7	[abl													Owned						
	version bate (Month/Day/Year) (Month/Day/Year) varive 3. Transaction Date Execution Date, if any (Month/Day/Year)		4. Trans	5. No fransaction code (Instr.) Sect Acq (A) c Disp		i. Number 6. Experivative Securities A) or Disposed of (D) (Instr.		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title of Sec Under	7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		11. Nature of Indirect Beneficial Ownership (Instr. 4)			
				Code	v	(A)	(D)					Title	or Nu of	mber							
\$2.67	12/19/2022						28,200	00 (7)		12/0	04/2023				\$0	450,000		D			
\$3.76	12/19/2022						15,000	0	(8)	02/0				,000	\$0	258	,840	840 D			
\$14.95	12/19/2022			M			6,688		(9)	02/	15/2028			688	\$0	273	,312	D			
	Stock	Stock	(First) (Midde ELLIS PHARMACEUTICALS, AM MA 0245 (State) (Zip) Table I Security (Instr. 3) Stock Stock Stock Stock Stock St	Security (Instr. 3) Conversion Or Exercise of Derivative Security (Month/Day/Year) Security (Instr. 3) Table II - Derivative Security (Month/Day/Year) Stock 12/19/202 Stock Stock	Amage	Apellis Scedric Apellis Scedric Apellis Scedific Apellis Scedific Apellis Ap	Apellis Pt	Apellis Pharma Security (Middle)	Apellis Pharmaceu	Apellis Pharmaceuticals Apellis Pharmaceuticals Apellis Pharmaceuticals	Apellis Pharmaceuticals, Inc	Apellis Pharmaceuticals, Inc. Application of Original Filed (Month/Day/Year) An I f Amendment, Date of Original Filed (Month/Day/Year)	Apellis Pharmaceuticals, Inc. Application of University Pharmaceuticals, Inc	Apellis Pharmaceuticals, Inc. APLS	Apellis Pharmaceuticals, Inc. Application, Inc. Appl	Apellis Pharmaceuticals. Inc. Apellis Pharmaceuticals. Inc. Application Ap	Apellis Pharmaceuticals_lne_{(First) (Middle) C(First) (Middle) SLLIS PHARMACEUTICALS, INC.	Apellis Pharmaceuticals, Inc. Apellis Pharmaceuticals, Inc	Apellis Pharmaceuticals Inc. [APLS Substitution Apple Appl	Apellis Pharmaceuticals. Inc. APLS Similar Application Applica	

- 1. This represents the cancellation of a PSU awards granted on 01/28/2021 that was originally reported in table I upon grant. The performance metrics were not met.
- 2. This is a scheduled exercise & sale from 10b5-1 plan adopted September 13, 2022 .
- 3. Sale price within range of \$1. Min. \$50.695 Max. \$51.680
- 4. Sale price within range of \$1. Min. \$51.695 Max. \$52.400
- 5. The securities are held by The Francois Grossi Trust, for which Juliana Grossi, the spouse of the reporting person, serves as trustee. The reporting person disclaims beneficial ownership over the shares held by the Francois Grossi Trust except to the extent of his pecuniary interest therein.
- 6. The securities are held by The Francois-DuBois Educational Trust, for which the Fiduciary Trust Company of New England serves as trustee. The reporting person disclaims beneficial ownership over the shares held by The Francois-DuBois Educational Trust except to the extent of his pecuniary interest therein.
- 7. This option was granted on December 5, 2013 and fully vested.
- 8. This option was granted on February 8, 2016 and fully vested.

9. This option was granted on February 16, 2018 and will vest as to 25% of the shares underlying the options on the first anniversary of the grant, with the remaining 75% of the shares underlying the options vesting in equal monthly installments thereafter through the fourth anniversary of the grant, subject to continued service.

/s/ David Watson, attorney-infact for Cedric François

12/21/2022

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.